Free Trial

Amarin Q3 2024 Earnings Report

Amarin logo
$0.44 -0.03 (-5.80%)
As of 03/28/2025 04:00 PM Eastern

Amarin EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.04
Beat/Miss
Missed by -$0.02
One Year Ago EPS
-$0.05

Amarin Revenue Results

Actual Revenue
$42.30 million
Expected Revenue
$43.82 million
Beat/Miss
Missed by -$1.52 million
YoY Revenue Growth
N/A

Amarin Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Remove Ads

Amarin Earnings Headlines

Amarin shareholder group urges board to initiate strategic review
Claim Your FREE Protection Guide
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...
Amarin announces additional in vitro data with EPA to be presented
See More Amarin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Amarin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amarin and other key companies, straight to your email.

About Amarin

Amarin (NASDAQ:AMRN), a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

View Amarin Profile

More Earnings Resources from MarketBeat